NASDAQ: PTGX

Protagonist Therapeutics Inc Stock Forecast, Predictions & Price Target

The consensus among 5 Wall Street analysts covering (NASDAQ: PTGX) stock is to Strong Buy PTGX stock.

Out of 5 analysts, 3 (60%) are recommending PTGX as a Strong Buy, 2 (40%) are recommending PTGX as a Buy, 0 (0%) are recommending PTGX as a Hold, 0 (0%) are recommending PTGX as a Sell, and 0 (0%) are recommending PTGX as a Strong Sell.

If you're new to stock investing, here's how to buy Protagonist Therapeutics stock.

(NASDAQ: PTGX) Protagonist Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.66%.

Protagonist Therapeutics's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast PTGX's revenue for 2023 to be $3,172,296,710, with the lowest PTGX revenue forecast at $2,883,906,100, and the highest PTGX revenue forecast at $3,460,687,320. On average, 2 Wall Street analysts forecast PTGX's revenue for 2024 to be $1,441,953,050, with the lowest PTGX revenue forecast at $865,171,830, and the highest PTGX revenue forecast at $2,018,734,270.

In 2025, PTGX is forecast to generate $4,056,675,355 in revenue, with the lowest revenue forecast at $346,068,732 and the highest revenue forecast at $7,498,155,860.

According to 5 Wall Street analysts that have issued a 1 year PTGX price target, the average PTGX price target is $37.00, with the highest PTGX stock price forecast at $41.00 and the lowest PTGX stock price forecast at $34.00.

On average, Wall Street analysts predict that Protagonist Therapeutics's share price could reach $37.00 by Nov 3, 2024. The average Protagonist Therapeutics stock price prediction forecasts a potential upside of 81.73% from the current PTGX share price of $20.36.

(NASDAQ: PTGX) forecast ROE is N/A, which is considered weak.